Orlance, Inc.
Publicly observedSeattle, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Seattle | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Orlance, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KH6YJYH55G53 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant11 Sept 2025Publicly observed
NIH SBIR/STTR award: Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals
USD 298,837.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant11 Sept 2025Publicly observed
NIH SBIR/STTR award: Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant8 Aug 2024Publicly observed
NIH SBIR/STTR award: Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant3 May 2024Publicly observed
NIH SBIR/STTR award: Gene Gun-delivered RNA vaccines.
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2023Publicly observed
NIH SBIR/STTR award: Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine
USD 977,255.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.